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Objective: The aim of this study was to investigate patterns of cortical atrophy associated with 
mild cognitive impairment  in a large sample of non-demented PD patients, and its relation with 
specific neuropsychological deficits.  
Methods: MRI and neuropsychological assessment were performed in a sample of 90 non-
demented PD patients and 32 healthy controls. All underwent a neuropsychological battery 
including tests that assess different cognitive domains: attention and working memory, 
executive functions, memory, language and visuoperceptual-visuospatial functions. Patients 
were classified according to their cognitive status as PD patients without mild cognitive 
impairment (n=43) and PD patients with mild cognitive impairment (n=47). Freesurfer software 
was used to obtain maps of cortical thickness for group comparisons and correlation with 
neuropsychological performance. 
Results: Patients with mild cognitive impairment  showed regional cortical thinning in parieto-
temporal regions, increased global atrophy (global cortical thinning, total gray matter volume 
reduction and ventricular enlargement), as well as significant cognitive impairment in memory, 
executive and visuospatial and visuoperceptual domains. Correlation analyses showed that all 
neuropsychological tests were associated with cortical thinning in parieto-temporal regions and 
to a lesser extent in frontal regions.  
Conclusion: These results provide neuroanatomic support to the concept of MCI classified 
according to Movement Disorders Society  criteria. The posterior pattern of atrophy in temporo-
parietal regions could be a structural neuroimaging marker of cognitive impairment in non-
demented PD patients. All the neuropsychological tests reflected regional brain atrophy but 









Parkinson’s disease is associated with cognitive decline [Aarsland et al., 2009; Elgh et al., 2009; 
Foltynie et al., 2004; Muslimovic et al., 2005] that may predict dementia at later stages 
[Aarsland et al., 2009; Janvin et al., 2006; Pedersen et al., 2013].Between 18.9 and 38.2% of 
patients meet mild cognitive impairment (MCI) criteria [Litvan et al., 2011a]. Indeed, the 
proportion of patients fulfilling MCI criteria increased from one-third to approximately 50% of 
patients without dementia after five years from diagnosis [Broeders et al., 2013]. There is a 
great variability in the description and proportion of subtypes of MCI in PD [Aarsland et al., 
2009; Caviness et al., 2007; Janvin et al., 2006], due perhaps to the number and type of tests 
used and the classification of the tests by domains.  
The recognition of PD patients with MCI (PD MCI) has led to studies searching for biological 
markers associated with this diagnosis. Several MRI studies have investigated the relationship 
between brain atrophy and specific cognitive deficits in non-demented PD, such as deficits in 
memory  [Brück et al., 2004; Camicioli et al., 2003; Ibarretxe-Bilbao et al., 2008; Junqué et al., 
2005; Litvan et al., 2012; Pereira et al., 2013; Riekkinen et al., 1998; Tam et al., 2005], verbal 
fluency [Pereira et al., 2009a], visuospatial and visuoperceptual ability [Pereira et al., 2009b] 
and decision-making and emotional processing [Ibarretxe-Bilbao et al., 2009]. Recently, Filoteo 
et al., using region-of-interest analyses, associated subtle changes in multiple cognitive 
domains with distinct patterns of regionally-specific volume changes in non-demented PD 
patients [Filoteo et al., 2014]. However, to the best of our knowledge, no published MRI studies 
have focused on whole brain neuroanatomical correlates of the different tests included in 
cognitive domains assessed by an extensive neuropsychological battery. 
Few studies have investigated the neuroanatomical correlates of MCI. Initially, voxel based 
morphometry (VBM) analyses showed that PD-MCI had reduced cortical gray matter (GM) 
density in the left middle frontal gyrus, precentral gyrus, left superior temporal lobe and right 
inferior temporal lobe in comparison with cognitively intact PD patients [Beyer et al., 2007]. In 
contrast, Song et al. reported gray matter density decreases in frontal regions of PD-MCI 
patients in comparison to PD without MCI (PD non-MCI) [Song et al., 2011]. Recently, VBM 
analyses with a large sample of 148 PD patients did not reveal any areas of significant GM loss 
in participants with PD-MCI compared with controls [Yarnall et al., 2014]. 
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In order to clarify these controversial results, certain methodological issues need to be 
addressed. VBM and volumetric analyses may be insufficient to detect early cortical changes in 
PD MCI patients. Recent studies using cortical thickness measures suggest that this method 
may be more sensitive than VBM to identify regional GM changes associated with PD [Pereira 
et al., 2012]. Cortical changes associated specifically with MCI in PD have not been 
investigated in depth. In a small sample, Biundo et al. showed significant regional thinning in 
right parietal-frontal areas and in left temporal-occipital areas in PD MCI in comparison with PD 
non-MCI [Biundo et al., 2013]. Studying a bigger sample, Pagonabarraga et al., using an 
uncorrected level of significance showed both increases and decreases in cortical thickness of 
PD MCI patients in comparison to PD non-MCI [Pagonabarraga et al., 2013], and Hanganu et 
al. did not find significant cortical thinning in PD MCI subjects compared with PD non-MCI, but 
detected a small cluster with increased thickness in the left middle temporal gyrus [Hanganu et 
al., 2013]. Recently, Pereira et al. studied a large multicentric cohort of drug-naïve PD patients 
with early PD, the authors found mainly temporal and parietal cortical thinning in the PD MCI 
group compared to PD non-MCI patients, using a cognitive-domain approach [Pereira et al., 
2014].  
In light of these previous results, the aims of this study were (1) to investigate whether different 
anatomical patterns of cortical atrophy distinguish PD patients with mild cognitive impairment 
from patients without cognitive impairment in a large sample of non-demented PD patients, and 
(2) whether different anatomical patterns of cortical atrophy are associated with 
neuropsychological deficits commonly related to specific cognitive domains. This is of crucial 
importance for validating MCI criteria, and may help to clarify the neural correlates of cognitive 




The study included 121 consecutive PD patients recruited from an outpatient movement 
disorders clinic (Parkinson’s Disease and Movement Disorders Unit, Department of Neurology, 
Hospital Clinic, Barcelona, Spain) and 49 healthy subjects who volunteered to take part in 
studies addressing age-related processes at the Institut de l’Envelliment (Aging Institute). The 
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inclusion criteria were: (i) fulfilling the UK PD Society Brain Bank (PDSBB) diagnostic criteria for 
PD [Daniel and Lees, 1993]; (ii) no surgical treatment with deep brain stimulation. The exclusion 
criteria were: (i) presence of dementia according to the Movement Disorders Society criteria 
(34), (ii) Hoehn and Yahr scale score >3 (iii) juvenile-onset PD, (iii) presence of psychiatric or 
neurological comorbidity, (iv) low global IQ estimated by the Vocabulary subtest of the Wechsler 
Adult Intelligence Scale, 3rd edition (scaled score ≤ 7 points), (vi) Mini-mental state examination 
(MMSE) score <25, (vii) presence of claustrophobia, (viii) pathological magnetic resonance 
imaging (MRI) findings other than mild white matter hyperintensities in long-TR sequences, and 
(ix) MRI artifacts.  
Ninety PD patients and 32 healthy volunteers were finally selected. Twelve patients and eight 
controls were excluded because they fulfilled criteria for dementia or other neurological disease, 
six PD patients for psychiatric comorbidity, one PD patient who scored higher than 3 on the 
H&Y scale, one PD patient who presented young-onset PD, three PD patients and one control 
who presented low global IQ scores, two PD patients for claustrophobia, three healthy subjects 
who did not complete the neuropsychological assessment, and two controls and two PD 
patients due to MRI artefacts. We also excluded four patients and three controls aged below 50 
years.  
Motor symptoms were assessed by means of the UPDRS-III, motor section. All PD patients 
were taking antiparkinsonian drugs, consisting of different combinations of L-DOPA, COMT 
inhibitors, MAO inhibitors, dopamine agonists and amantadine. 
This study was approved by the ethics committee of the University of Barcelona. Written 




We selected a neuropsychological battery to assess cognitive functions usually impaired in PD 
[Aarsland et al., 2009; Muslimovic et al., 2005]. This battery is recommended by the Movement 
Disorder Society task force to evaluate cognitive functions in PD  [Daniel and Lees, 1993; Litvan 
et al., 2011b], and is able to detect mild cognitive impairment in PD (Level I or Level II criteria 
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for PD-MCI, bar language, for which a single measure was used [Litvan et al., 2012]. Attention 
and working memory were assessed with the Trail Making Test (TMT) (in seconds), part A 
(TMT-A) and part B (TMT-B), Digit Span Forward and Backward and the Stroop Color-word 
Test and Symbol Digits Modalities Tests (SDMT); executive functions were evaluated with 
Phonemic (words beginning with the letter “p” in one minute) and Semantic (animals in one 
minute) fluencies; language was assessed by the total number of correct responses in the short 
version of the Boston Naming Test (BNT), memory through total learning recall (sum of correct 
responses from trial I to trial V) and delayed recall (total recall after 20min) through scores on 
Rey’s Auditory Verbal Learning Test (RAVLT). Visuospatial and visuoperceptual functions were 
assessed with Benton’s Judgement of Line Orientation (JLO) and Visual Form Discrimination 
(VFD) tests. 
Initially, z scores for each test and for each subject were calculated based on the control 
group’s means and standard deviations. Expected z scores adjusted for age, sex and education 
for each test and each subject were calculated based on a multiple regression analysis 
performed in the healthy control group [Aarsland et al., 2009].  
We classified subjects as having MCI if the z score for a given test was at least 1.5 lower than 
the expected score in at least two tests in one domain, or in at least one test per domain in at 
least two domains. As expected [Muslimovic et al., 2005], most subjects with abnormalities had 
deficits in more than one function, precluding the creation of patient groups with single-domain 
impairments. Patients’ cognitive complaints were recorded during the clinical interview.  
Z composite scores were computed in order to obtain global cognitive measures (attention and 
working memory, executive, memory and visuospatial/ visuoperceptual functions).  
Neuropsychological and Clinical Statistical Analysis 
All statistical analyses were performed using SPSS Statistics 20, release version 20.0.0 
(Armonk, NY, http://www-01.ibm.com/software/analytics/spss/). Statistical significance threshold 
was set at p<0.05. Pearson’s chi-square test was used to compare categorical variables (sex 
and Hoehn and Yahr stage). Separate-variance test (Welch t) was used to test between-group 
differences (HC, PD MCI, PD non-MCI) in quantitative clinical and demographic variables. 
ANCOVAs including age and education as confounding variables were used to compare the 
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performance on neuropsychological tests and composite scores for each domain. Bonferroni 
correction was used to control for the number of intergroup comparisons. 
Image acquisition  
Magnetic resonance images were acquired with a 3T scanner (MAGNETOM Trio, Siemens, 
Germany). The scanning protocol included high-resolution 3-dimensional T1-weighted images 
acquired in the sagittal plane (TR=2300 ms, TE=2.98 ms, TI 900 ms, 240 slices, FOV=256 mm; 
matrix size=256x256; 1 mm isotropic voxel) and axial FLAIR sequence (TR=9000 ms, TE=96 
ms). 
Cortical thickness  
Cortical thickness was estimated using the automated FreeSurfer stream (version 5.1; available 
at: http://surfer.nmr.harvard.edu). The procedures carried out by FreeSurfer software include 
removal of non-brain data, intensity normalization [Sled et al., 1998], tessellation of the gray 
matter/white matter boundary, automated topology correction [Fischl et al., 2001; Ségonne et 
al., 2007] and accurate surface deformation to identify tissue borders) [Dale et al., 1999; Dale 
and Sereno, 1993; Fischl and Dale, 2000]. Cortical thickness is then calculated as the distance 
between the white and gray matter surfaces at each vertex of the reconstructed cortical mantle 
[Fischl and Dale, 2000]. In our study, results for each subject were visually inspected to ensure 
accuracy of registration, skull stripping, segmentation, and cortical surface reconstruction. Maps 
were smoothed using a circularly symmetric Gaussian kernel across the surface with a full width 
at half maximum (FWHM) of 15 mm. 
Comparisons between groups were assessed using a vertex-by-vertex general linear model. 
The model included cortical thickness as a dependent factor and diagnosis (controls, PD non-
MCI, PD MCI) as an independent factor, and also included age and education as nuisance 
variables (https://surfer.nmr.mgh.harvard.edu/fswiki/FsgdFormat). All results were corrected for 
multiple comparisons by using a pre-cached cluster-wise Monte-Carlo Simulation. Significance 
level was set at p<0.05.  
In the PD patient group, the vertex-by-vertex general linear model was used to assess the 
relationship between cortical thickness and neuropsychological tests. Positive and negative 
associations between a specific neuropsychological test and cortical thickness were analyzed 
using Qdec. Initially, a simple model without covariates was tested for each neuropsychological 
8 
 
measure. Complementarily, we performed a conservative analysis of covariance including age, 
education and gender as confounding variables. An initial vertex-wise threshold was set to 
p=0.005 to find clusters. In order to avoid clusters appearing significant purely by chance (i.e., 
false positives), Monte-Carlo simulation with 10,000 repeats was tested (absolute value). 
Results were reported at cluster-wise probability significance level set at p<0.05. 
 
Global atrophy measures  
Global average thickness for both hemispheres was calculated ((left hemisphere thickness*left 
hemisphere surfarea)+(right hemisphere thickness*right hemisphere surface area))/(left 
hemisphere surface area+right hemisphere surface area)).  
Total GM volume and total subcortical volumes, as well as mean lateral ventricular volume and 
estimated Total Intracranial Volume (eTIV) were obtained automatically via whole brain 
segmentation [Fischl et al., 2002]. An ANCOVA including eTIV, age and education was used to 
compare subcortical volumes between groups. Significant p values were adjusted using post-
hoc Bonferroni tests considering the number of intergroup comparisons.  
 
Results 
Forty-seven patients (52.2%) fulfilled the criteria for MCI. Table 1 shows sociodemographic and 
clinical data and the corresponding group comparisons.  
Insert Table 1 
Neuropsychological differences between groups.  
Table 2 shows differences in neuropsychological performance between groups. MCI patient 
scores were significantly worse than those of non-MCI patients and healthy controls in all tests 
except Forward and Backward Digits. Forty-two patients (46.6%) showed impairments in 
attention and working memory, 31 (34.4%) in memory, 26 (28.8%) in executive and also 
visuoperceptual and visuospatial domains, and only four (4.4%) in language. 
Insert Table 2 
Global atrophy comparison between groups 
There were significant differences in global atrophy between healthy controls and PD patients 
groups according to MCI status. PD MCI patients showed decreased total mean thickness and 
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total GM volume, as well as increased mean lateral ventricle volume in comparison to healthy 
controls and PD non-MCI. There were no significant differences in total subcortical volume 
(Table 3).  Finally, there were no significant results after the inclusion of disease duration as a 
nuisance variable in the covaried model.  
Insert Table 3 
Cortical thickness comparison between groups  
Surface-based cortical thickness analyses showed a group effect according to cognitive status 
(Figure 1). PD MCI (PD MCI < HC ) showed cortical thinning in widespread bilateral regions, 
including parietal (superior and inferior, supramarginal and also precuneus regions), temporal 
(posterior middle temporal, inferior temporal, fusiform and parahippocampal regions) and 
occipital cortices (bilateral posterior occipital), but also in left frontal superior and rostral middle 
areas. There were significant differences between controls and PD non-MCI (PD non-MCI < 
HC) specifically in bilateral superior parietal regions. PD MCI (PD MCI < PD non-MCI) showed 
significant thinning in right precuneus and supramarginal regions compared to PD non-MCI. 
There were no significant results after including disease duration as a nuisance factor in the co-
varied model. 
Insert Figure 1 and supplementary material Table 1 
Correlations between neuropsychological tests and cortical thickness in PD patients 
Vertex-wise regression analyses showed correlations between regional cortical thickness and 
neuropsychological test performance (Supplementary Material).  We found a common posterior 
atrophy pattern for all the neuropsychological tests evaluated, and there were no specific 
patterns of atrophy related to neuropsychological domains. 
Stroop Test (Words, Colours and Word-Colours), TMT A, Semantic fluency and RAVLT total 
learning performance correlated with gray matter thinning in bilateral medial and lateral areas. 
Performance on VFD, JLO and TMT B was associated only with medial temporal-parietal 
atrophy. Atrophy in anterior regions, mostly left superior frontal gyrus, also correlated with 
Stroop Test, TMTA, SDMT, phonemic fluency and RAVLT total learning. In addition, negative 
correlations with SDMT and JLO were also found in rostral middle frontal gyrus (Supplementary 
Figure 1 and material table 2). After controlling for the effect of age, education, and gender, only 
Stroop Words Test and Semantic fluency showed a significant positive correlation with cortical 
10 
 
thickness. Stroop Words Test correlated with left medial orbitofrontal, right superior temporal 
and right insula. Semantic fluency correlated with right precuneus and lingual gyrus thickness. 
(Figure 2. and supplementary material 3). There were no significant results after including 
disease duration as a nuisance factor in the covaried model.  
Insert Figures 2  
 
Discussion 
Patients with MCI showed a posterior pattern of atrophy, characterized by cortical thinning in the 
bilateral superior parietal and supramarginal regions and in the inferior temporal area, 
parahippocampal gyrus, fusiform gyrus and precuneus. Cortical thinning was also observed in 
the  left rostral frontal region. Moreover, PD MCI and PD non-MCI patients differed in right 
lateral parietal regions and precuneus.  
Our results of cortical thickness reductions in the parietal, temporal and frontal regions could be 
related to previous PET data [Garcia-Garcia et al., 2012] showing that PD-MCI patients 
exhibited reduced FDG uptake in the parietal and occipital lobes and in localized areas of the 
frontal and temporal lobes compared with controls. In addition, longitudinal neuropsychological 
studies suggest that the dementia process is heralded by posterior-cortically-based cognitive 
deficits [Williams-Gray et al., 2007; Williams-Gray et al., 2009]. In sum, parieto-occipital 
changes seem to correspond to the deterioration that may eventually lead to dementia, possibly 
reflecting gradual loss of synaptic terminals, dendritic arborisation and size of neuronal cell 
bodies.  
In our study, PD groups differed by degree of atrophy in right lateral parietal regions and the 
precuneus. This finding, together with the right asymmetry of atrophy detected in the PD non-
MCI group compared to controls, suggested an asymmetric pattern of deterioration, initially 
involving parietal and temporal regions, and progressively widespread to bilateral atrophy. 
Asymmetric atrophy has been found in previous studies when PD patients were compared to 
controls [Pereira et al., 2012]. 
Recently, PD MCI patients have been studied using cortical thickness measures.  However, no 
consensus has been reached in relation to cortical thickness differences between PD MCI and 
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PD non-MCI; both increases and decreases have been reported in PD MCI, probably due to 
small sample sizes [Biundo et al., 2013; Hanganu et al., 2013; Pagonabarraga et al., 2013]. As 
expected, we observed thinning in PD MCI involving the sumpramarginal gyrus and the 
precuneus.  
In addition to differences in regional cortical thickness, PD MCI patients had a reduction of 
global GM volume together with increased ventricular volume in comparison to PD non-MCI and 
healthy controls. These results, similar to those of previous studies [Apostolova et al., 2012; 
Dalaker et al., 2010; Weintraub et al., 2011], confirm that cognitive deficits seen in PD MCI are 
related to structural brain changes, probably in combination with neurochemical changes.  
The current study also aimed to establish whether specific neuropsychological tests used in 
clinical practice reflect the degree of regional atrophy in PD patients. Cognitive domains are 
defined under the assumption that they represent specific functions mediated by specific brain 
regions. The ‘anterior’ (frontal) pattern is putatively associated with executive functions, the 
‘posterior’ (temporo-parietal) pattern with visuospatial and visuoperceptual functions, and 
hippocampal degeneration with the amnestic pattern [Lezak, 2004]. Grouping different tests into 
a single function without knowing the specific correlates of each test may generate confusion. 
The study of neuroanatomical correlates of specific tests is the first step in the discussion of 
domains and in determining whether subtypes of mild cognitive impairment exist in PD, and 
consequently whether they are useful in predicting the evolution to dementia. In line with this 
statement, our results showed a common posterior atrophy pattern for all the 
neuropsychological tests evaluated. Only the Stroop Test, SDMT and phonemic fluency, 
classified by recent guidelines [Litvan et al., 2012] as measures of attention and executive 
function respectively, had an extended pattern including medial anterior regions.  We did not 
observe any specific  dorsolateral prefrontal or limbic pattern of correlations. Analysing the 
global patterns of correlations, a group of tests including Stroop Test (Words, Colors and Word-
Colors), TMT-A, Semantic fluency and RAVLT total learning correlated with extensive gray 
matter loss involving bilateral medial and lateral cortical regions, whereas VFD, JLO and TMT-B 
only correlated with medial temporal-parietal regions. Analyses of covariance only showed a 
positive correlation between semantic fluency and temporal-parietal regions and a positive 
correlation between Stroop words and left medial orbitofrontal, right superior temporal and right 
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insular regions. In sum, we did not find specific patterns of atrophy related to the 
neuropsychological domains, either with or without the use of covariates in the analyses.  
Interestingly, semantic fluency performance remained significantly correlated with the 
precuneus after controlling for the effects of age, education, and gender. These results agree in 
part with current pathophysiological models that dissociate the substrates and prognostic values 
of different types of cognitive impairment in PD, and show that tests with posterior cortical bases 
(semantic fluency and ability to draw an interlocking pentagon) reflecting probable non-
dopaminergic cortical Lewy body or Alzheimer’s type pathology were associated with dementia, 
whereas frontostriatal executive deficits were not [Williams-Gray et al., 2009]. Our results 
indicate that semantic fluency is an easily administered test that should be included in the 
neuropsychological assessment of PD patients. 
The consecutive recruitment of PD patients from an outpatient movement disorders clinic 
involves certain differences in clinical and demographical variables between PD groups. In this 
regard, disease duration was longer in PD-MCI than PD non-MCI patients. In our study, 
additional analyses including disease duration as nuisance variable in the co-varied models did 
not show significant results. A previous study has shown that neurodegeneration is likely to 
occur faster in PD patients with MCI [Hanganu et al., 2013]. Cortical degeneration was more 
advanced in patients who have PD MCI than in those without at the same stage of disease. In 
accordance with previous longitudinal studies [Williams-Gray et al., 2007; Williams-Gray et al., 
2009], disease duration is correlates with PD patients’ deterioration, including cognitive 
impairment and brain atrophy. In this sense, controlling for the effects of disease duration could 
represent an overcorrection, masking actual intergroup effects.  
One possible limitation of our study is that, despite the inclusion of a variety of tests in the main 
cognitive domains defined in recent guidelines (attention and working memory, executive 
functions, memory and visuospatial and visuoperceptive functions) [Litvan et al., 2011b] we did 
not include the same number of tests in each cognitive domain, and language was assessed 
only with the BNT. This limitation may have raised the possibility of false negative cases in the 
PD non-MCI group, but would not have affected the classification of subjects currently included 
in PD MCI group.  
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In sum, degeneration was characterized by a posterior pattern of atrophy mostly involving 
posterior parietal-temporal areas, which extended to frontal regions in the PD MCI group 
compared to healthy controls. All the neuroanatomical correlates associated with 
neuropsychological tests involve this posterior pattern of atrophy, semantic fluency being the 
neuropsychological test with the most significant association. Our findings therefore suggest the 
presence of posterior structural degenerative brain changes in PD MCI patients, evidencing a 
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Age (yrs.) 64.69±8.63 60.77±10.51 67.72±9.71 5.243/0.007 
Sex 
(female/male) 
17/17 29/21 23/17 0.61 χ /0.738 
Years of 
education 
11.00±4.15 12.02±5.05 9.19±5.24 3.47/0.036 
MMSE 29.69±0.47 29.47±0.74 28.68±1.29 11.998/<0.001 
BDI 6.00±5.65 8.71±5.41 12.63±6.41 11.174/<0.001 
Disease 
duration 
 6.23±4.05 9.73±6.37 9.845/0.002 







 14/5/19/3/2 8/0/25/6/8 11.900 χ/0.018 
UPDRS-III  13.16±7.67 17.79±11.07 6.378/0.023 
 
MMSE: mini-mental state examination. BDI: Beck’s Depression Inventory-II scores. Disease 
duration: duration of motor symptoms, in years. LEDD: Levodopa equivalent daily dose, in mg. 
HY: Hoehn and Yahr scale. Pearson’s chi-square (χ).  Age showed significant differences 
between PD MCI and PD non-MCI patients (p=.0003, Bonferroni correction). MMSE showed 
significant differences between PD MCI and both PD non-MCI and HC (p<.001, Bonferroni 
correction). BDI showed significant differences between PD MCI and both PD non-MCI (p<.010, 









Table 2. Neuropsychological performance results for healthy controls and Parkinson’s disease 


































































































10.283   
(<0.001)  





























































Visoperceptual/visuospatial  0.01  -0.05  -1.10  16.78 (<0.0001) 
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(0.71) (0.67) (1.08) 








Impaired subjects per domain 
Attention/Working memory*  4 11 42  
Executive* 0 4 26  
Memory* 1 5 31  
Visoperceptual/visuospatial*  0 4 26  
Language* 1 3 4  
 
MCI patients’ scores were significantly worse than non-MCI patients’ and healthy controls’ 
(p<.05, Bonferroni correction). * Number of subjects impaired in one or more tests in this 
domain. In the healthy control group, no subjects showed impairments in more than one test, 
i.e., none fulfilled criteria for MCI. Trail Making Test (TMT) part A (TMT A) and part B (TMT B), 
Symbol Digits Modalities Tests (SDMT); short version of the Boston Naming Test (BNT), Rey’s 
Auditory Verbal Learning Test (RAVLT); Benton’s Judgement of Line Orientation (JLO) and 
Visual Form Discrimination (VFD). 
 
Table 3. Global atrophy results for healthy controls and Parkinson’s disease patients according 












Global thickness (mm) 2.49 (0.09) 2.47 (0.10) 2.41 (0.10 6.412 (0.002) 
Total GM (cm3) 610.36 (51.79) 605.06(59.68) 589.95 (57.85) 3.652 (0.029)* 
Subcortical GM (cm3) 168.97(20.07)  173.14(20.98) 171.02 (18.44) 1.533 (0.220)* 
Lateral ventricles (cm3) 9.60 (4.05) 10.65 (5.57) 13.64 (7.85) 3.058 (0.051)* 
 
*ANCOVA analyses with age, education and eICV as confounding variables. Global cortical 
thickness showed significant differences between HC and PD MCI patients (p<0.006, Bonferroni 
correction). Total GM showed significant differences between HC and PD non-MCI patients 
(p=0.031, Bonferroni correction). Mean lateral ventricular volumes showed significant 









Figure 1. Vertex wise comparison of cortical thickness between healthy controls (HC), 
Parkinson’s disease patients without mild cognitive impairment (PD non-MCI) and Parkinson’s 
disease patient with mild cognitive impairment (PD MCI), after controlling for the effect of age 





















Figure 2. Significant correlation between cortical thickness and neuropsychological tests, after 
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Supplementary Material Table 1. Cortical thickness for healthy controls and 
Parkinson’s disease patients according to MCI status, after controlling for the effect 
of age and education.  
 
Cortical region Size 
(mm2) 
MNI  






HC > PD nonMCI 
RH Superior Parietal 2219.34 27.1 -60.5 45.0  4.001 0.0020 
LH Superior Parietal  2398.29 -19.8 -72.2 38.0 2.972 0.0013 
HC > PD MCI 
RH Superior Parietal 27428.22 27.4 -60.0 45.8 5.660 0.0010 
LH Lateral Occipital  24385.79 -24.9 -94.8 14.1 5.740 0.0001 
PD nonMCI > PD MCI 
RH Supramarginal  1580.07 53.1 -26.5 37.9 3.291 0.0260 
Precuneus 2764.79 8.0 -66.8 29.8 2.764 0.0003 
 
* MNI305 space. Results were obtained using Monte Carlo simulation with 10.000 
iterations applied to cortical thickness maps to provide clusterwise correction for 
multiple comparisons (1.3). Significant clusters were reported at p<0.05. z-Max 









Supplementary Material Table 2. Cortical areas showing significant correlation 












R Superior frontal -13.9   41.4   13.5   1016.84     5.728    0.0002   
R Fusiform -30.5  -63.9   -5.9   1430.51     5.327     0.0001   
R Insula -34.4  -15.3   17.9   5406.54     4.868   0.0001   
R Banksts -55.3  -48.9    4.2   1556.88     4.708   0.0001   
R Posterior cingulate -5.7  -26.9   36.9   2820.44      3.966    0.0001   
L Insula 35.9  -10.4   18.6   7124.40      6.664   0.0001   
L Fusiform 32.0  -75.0   -4.1   1783.32      5.145    0.0001  
L Supramarginal 57.2  -23.8   37.7   2178.13      5.142   0.0001   
L Precuneus 5.7  -63.8   32.0   1200.89       4.216    0.0001   
L Superiorparietal 33.6  -35.3   36.2   688.49      3.258   0.0078  
Stroop Colours 
L Insula -31.2  -23.8   15.3 1810.45 6.218 0.0001 
L Posterior cingulate -5.5  -31.0   34.9 1741.69 5.662 0.0001 
L Superior frontal -9.7    4.1   45.0 2140.27 5.101 0.0001 
L Fusiform -30.5  -65.8   -4.3 974.31 4.982 0.0005  
L Inferior parietal -48.3  -61.2   12.5 964.95 4.812 0.0006   
L Precentral -13.8  -10.8   60.1 819.32 3.933 0.0017 
R Insula 32.6  -20.3   16.5 5343.71 7.405 0.0001   
R fusiform 32.1  -72.9   -5.6 1797.47 6.397 0.0001   
R Precuneus 5.7  -63.0   30.0 1820.89 4.630 0.0001   
R middle temporal 53.4  -56.3    8.0 868.00 4.431 0.0008   
R superior temporal 42.5    4.9  -21.6 806.48 4.252 0.0025   
R superior frontal 20.6   12.5   51.3 691.36 4.126 0.0075   
28 
 
R supramarginal 34.0  -35.0   36.2 1343.18 3.864 0.0001   
R Paracentral 6.3  -22.9   51.0 603.83 3.774 0.0165   
R lingual 22.2  -50.2   -3.5 689.39 3.417 0.0077   
R superior parietal 26.3  -67.9   26.2 491.82 3.107 0.0406 
Stroop Words and Colours 
L fusiform -34.3  -44.1   -8.9 2038.27 7.546 0.0001 
L insula -34.6  -13.7   17.8 6865.11 7.153 0.0001 
L precuneus -12.2  -54.2   12.3 3555.51 5.765 0.0001 
L superiorfrontal -9.8    4.7   43.4 2574.41 5.309 0.0001 
L precentral -50.8   -0.5   37.7 705.52 4.235 0.0049 
L supramarginal -46.3  -37.1   40.7 678.20 3.663 0.0074 
L lateralorbitofrontal -41.2   25.8  -10.9 453.99 3.565 0.0473 
R superiortemporal 44.2    1.1  -19.2 9480.53 7.191 0.0001 
R fusiform 28.1  -44.5  -11.4 3165.48 6.054 0.0001 
R precuneus 4.7  -55.0   18.6 3700.90 5.696 0.0001 
R paracentral 6.1  -21.9   50.2 682.05 5.126 0.0082 
R rostralmiddlefrontal 24.9   40.1   17.0 467.44 -4.410 0.0499 
R precentral 54.3    1.2   36.3 870.57 4.095 0.0008 
R superiorfrontal 22.7    1.8   43.4 643.42 3.817 0.0116 
TMT A 
L superiortemporal -45.9  -37.3   12.4 2596.58 -5.034 0.0001 
L posteriorcingulate -5.2  -30.0   34.7 2812.62 -4.652 0.0001 
L inferiorparietal -47.6  -61.2   12.3 501.20 -4.567 0.0330 
L fusiform -34.3  -44.1   -8.9 1030.37 -4.067 0.0002 
R superiortemporal 39.8    5.2  -23.1 5966.78 -6.499 0.0001 
R lingual 7.2  -66.7    5.0 2678.34 -5.452 0.0001 
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R middletemporal 54.1  -54.4   10.3 894.92 -4.879 0.0006 
R precuneus 8.0  -51.5   20.9 1454.84 -3.957 0.0001 
R precentral 39.0  -11.0   55.1 1442.20 -3.345 0.0001 
TMT B 
R precuneus -5.3  -55.8   20.0 635.93 -3.845 0.0099 
R fusiform -30.4  -66.1   -6.1 591.22 -3.541 0.0145 
SDMT 
L precuneus -5.3  -58.2   17.3 2789.11 6.323 0.0001 
L fusiform -35.4  -42.4   -8.7 1382.66 5.407 0.0001 
L superiortemporal -45.1  -37.6   12.8 944.63 5.318 0.0006 
L inferiorparietal -48.2  -61.5   11.7 1515.09 3.858 0.0001 
L superiortemporal -47.7  -17.5   -0.5 580.28 3.378 0.0164 
L superiorfrontal -13.4   19.3   30.2 938.31 3.207 0.0006 
R rostralmiddlefrontal 23.8   41.2   17.8 3095.34 -5.933 0.0001 
R precuneus 8.1  -50.1   20.3 2054.89 5.896 0.0001 
R supramarginal 50.0  -34.7   17.7 2941.42 5.577 0.0001 
R fusiform 29.1  -52.5   -8.5 1631.70 5.347 0.0001 
R superiortemporal 42.6    7.0  -22.2 1025.13 4.787 0.0002 
Digits Backwards 
R  superiortemporal 51.5    7.4  -16.4 679.70 3.256 0.0117 
Semantic Fluency  
L posteriorcingulate -5.6  -27.9   37.5 2460.93 5.147 0.0001 
L fusiform -34.3  -43.0  -
10.0 
1153.99 5.021 0.0001 
L insula -31.7  -28.4   13.2 3103.69 4.589 0.0001 
L bankssts -53.0  -39.4    7.2 1246.19 4.373 0.0001 
R lingual 22.3  -46.4   -4.6 2858.65 6.853 0.0001 
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R precuneus 4.6  -55.2   19.8 2581.56 6.552 0.0001 
R superiortemporal 59.6   -6.2    0.1 6365.59 5.248 0.0001 
R middletemporal 57.2  -56.8    6.3 486.53 4.573 0.0427 
R rostralmiddlefrontal 25.4   39.8   16.7 862.24 -4.000 0.0011 
R inferiorparietal 52.2  -49.5   31.1 484.87 3.942 0.0436 
Phonemic Fluency 
L superiorfrontal -13.1   42.5   14.2   817.27     5.176    0.0019   
L superiortemporal -51.4   -2.9   -6.6   911.90     4.527    0.0007   
L fusiform -30.6  -65.2   -5.0   729.44     4.023   0.0041   
L posteriorcingulate -13.6  -11.2   38.7   529.75     3.413   0.0265   
R superiortemporal 44.0    1.1  -19.4 2135.47 6.585 0.0001 
R precuneus 23.0  -55.9   19.9 1612.36 5.257 0.0001 
R postcentral 37.7   -6.1   16.7 1074.58 5.004 0.0003 
R superiortemporal 60.2  -18.3   -0.0 1108.06 4.228 0.0003 
R lingual 25.3  -59.4   -1.6 972.18 3.573 0.0004 
RAVLT TOTAL 
L fusiform -29.9  -64.5   -2.1 823.29 5.415 0.0015 
L inferiorparietal -48.0  -61.4   10.4 566.60 4.858 0.0188 
L precuneus -5.9  -56.8   23.9 1469.20 3.738 0.0001 
L transversetemporal -48.5  -20.5    7.2 488.49 3.581 0.03630 
L precuneus -8.9  -41.5   45.7 522.68 3.434 0.02830 
L caudalanteriorcingulate -11.3   31.8   16.4 718.86 3.376 0.00470 
L fusiform -29.9  -64.5   -2.1 823.29 5.415 0.00150 
R middletemporal 53.5  -57.2    7.4 5191.17 5.423 0.00010 
R fusiform 31.4  -39.6  -13.5 2238.94 5.073 0.00010 




L insula 32.3  -26.5   13.8 651.27 4.228 0.01450 
JLO 
L precuneu -4.4  -58.6   19.5 1019.66 4.380 0.00020 
L fusiform -28.9  -71.7   -4.2 714.35 3.710 0.00480 
R precuneus 6.6  -56.7   36.4 1486.99 5.447 0.00010 
R fusiform 28.4  -69.9   -3.4 944.91 5.112 0.00050 
R superiortemporal 41.2    1.9  -20.7 743.64 5.054 0.00680 
R rostralmiddlefrontal 18.9   58.6    8.5 764.63 -3.801 0.00590 
VFD 
R superiortemporal 51.1    8.9  -16.1 523.83 5.831 0.03930 
R lingual 7.4  -67.1    4.4 571.40 4.951 0.02570 
 
JLO: Judgment Line Orientation; RAVLT: Rey Auditory Verbal Learning Test; TMT: 
Trail Making Test; VFD: Visual Form Discrimination; L= Left hemisphere; R= Right 
hemisphere.  Results were obtained using Monte Carlo simulation with 10,000 
iterations applied to CTh maps to provide clusterwise correction for multiple 
comparisons 2.3. Significant clusters were reported at p<0.05. * MNI305 space. z-












Supplementary Material Table 3. Cortical areas showing significant correlation 
between cortical thickness and neuropsychological tests after controlling for the 












Semantic Fluency  
R Lingual  20.3  -45.9   -5.4   657.55     6.051   0.0098   
R Precuneus 13.3  -42.5   37.2 494.59      2.753    0.0398   
Stroop P 
L medialorbitofrontal -6.4   55.6  -12.1   651.88      3.686    0.0088   
L superiortemporal 44.2    4.5  -20.4   533.79      3.092    0.0266 
L insula 33.0   10.1   11.1   634.09      4.132    0.0121 
 
Results were obtained using Monte Carlo simulation with 10,000 iterations applied 
to CTh maps to provide clusterwise correction for multiple comparisons 2.3. 
Significant clusters were reported at p<0.05. * MNI305 space. z-Max indicates the 











Supplementary figure 1. Significant correlation between cortical thickness and 






















Supplementary figure 2.  Mean cortical thickness of significant clusters from verex-
wise comparison between healthy controls (HC), Parkinson’s disease patients 
without mild cognitive impairment (PD non-MCI) and Parkinson’s disease patient 
with mild cognitive impairment (PD MCI), after controlling for the effect of age and 
education.  
 
 
 
 
